A new coordination mode for (pyrid-2-yl)thiolate (L) ligands: Synthesis and characterization of [Ru6(μ3-H)(μ5-κ-L)(μ-CO)(CO)15]

The hexaruthenium cluster complexes [Ru₆(μ₃-H)(μ₅-κ²-L)(μ- CO)(CO)₁₅], HL = 2-mercaptopyridine (1) and 2-mercapto-6-methylpyridine (2), have been prepared by heating [Ru₃(CO)₁₂] with 0.5 equiv. of HL in THF at reflux temperature. An X-ray diffraction study on a crystal of complex 2 has determined that its metallic skeleton, a basal-edge-bridged square pyramid, is hold up by a (6-methylpyrid-2-yl)thiolate ligand. This ligand is attached to the four basal ruthenium atoms of the pyramid through the sulfur atom and to the edge-bridging ruthenium atom through the nitrogen atom. Such a coordination mode is unprecedented for (pyrid-2-yl)thiolate ligands.     

Study on using high injection voltage and spiral inflector in the central region of VEC

A feasibility study of using high injection voltage and spiral inflector in the present heavy ion central region of VEC is described. Conditions necessary for waist-to-waist transfer of the ion beam in the hole lens of main magnet have been obtained. The results of orbit studies of a variety of heavy ions indicate that a spiral inflector can be used in the central region.     

Reactions of phthalazine, quinazoline, 4,7-phenanthroline and 2,3'-bipyridine with ruthenium carbonyl

The reactions of [Ru(3)(CO)(12)] with four aromatic diazines have been studied in THF at reflux temperature. With phthalazine (L(1)), the compound [Ru(3)(μ-κ(2)N(2)N(3)-L(1))(μ-CO)(3)(CO)(7)] (1), which contains an intact phthalazine ligand in an axial position bridging an Ru-Ru edge through both N atoms, is initially formed but it reacts with more phthalazine to give [Ru(3)(κN(2)-L(1))(μ-κ(2)N(2)N(3)-L(1))(μ-CO)(3)(CO)(6)] (2), in which a π-π stacking interaction between the aromatic rings of both ligands determines their position in cluster axial sites on the same face of the Ru(3) triangle. With quinazoline (HL(2)), the cyclometalated hydrido decacarbonyl derivative [Ru(3)(μ-H)(μ-κ(2)N(3)C(4)-L(2))(CO)(10)] (3) is initially produced but it partially decarbonylates under the reaction conditions to give [Ru(6)(μ-H)(2)(μ-κ(2)N(3)C(4)-L(2))(μ(3)-κ(3)-N(1)N(3)C(4)-L(2))(CO)(19)] (4), which results from the displacement of a CO ligand of 3 by the uncoordinated N(1) atom of another molecule of 3. With 4,7-phenanthroline (H(2)L(3)), the stepwise formation of the cyclometalated derivatives [Ru(3)(μ-H)(μ-κ(2)N(4)C(3)-HL(3))(CO)(10)] (5) and two isomers of [Ru(6)(μ-H)(2)(μ(4)-κ(4)N(4)C(3)N(7)C(8)-L(3))(CO)(20)] (6a, 6b) takes place. In compounds 6a and 6b, two Ru(3)(μ-H)(CO)(10) trinuclear units are symmetrically (C(2) in 6a or C(S) in 6b) bridged by a doubly-cyclometalated 4,7-phenanthroline ligand. With 2,3'-bipyridine (HL(4)), two products have been isolated, [Ru(3)(μ-H)(μ-κ(2)N(3')C(4')-L(4))(CO)(10)] (7) and [Ru(3)(μ-H)(μ-κ(3)N(2)N(3')C(2')-L(4))(CO)(9)] (8). While compound 7 contains an N(3')C(4')-cyclometalated 2,3'-bipyridine, in compound 8 an N(3')C(2')-cyclometalation is accompanied by the coordination of the N(2) atom of the remaining pyridine fragment. The structures of compounds 2, 3, 4, 6a and 8 have been determined by X-ray diffraction crystallography.     

Predicting Inclusion Behaviour and Framework Structures in Organic Crystals

We have used well‐established computational methods to generate and explore the crystal structure landscapes of four organic molecules of well‐known inclusion behaviour. Using these methods, we are able to generate both close‐packed crystal structures and high‐energy open frameworks containing voids of molecular dimensions. Some of these high‐energy open frameworks correspond to real structures observed experimentally when the appropriate guest molecules are present during crystallisation. We propose a combination of crystal structure prediction methodologies with structure rankings based on relative lattice energy and solvent‐accessible volume as a way of selecting likely inclusion frameworks completely ab initio. This methodology can be used as part of a rational strategy in the design of inclusion compounds, and also for the anticipation of inclusion behaviour in organic molecules.     

Molecular interactions of new pregnenedione derivatives

The in vitro inhibitory activity of five new progesterone derivatives: 17alpha-hydroxy-16beta-methylpregna-1,4,6-triene-3,20-dione 1; 16beta-methyl-17alpha-toluoyloxypregna-1,4,6-triene-3,20-dione 2; 17alpha-hydroxy-6-methylenepregn-4-ene-3,20-dione 3; 6-methylene-17alpha-toluoyloxypregn-4ene-3,20-dione 4 and 17alpha-(p-bromobenzoyloxy)-6-methylenepregn-4-ene-3,20-dione 5 was determined. These compounds were evaluated as 5alpha-reductase inhibitors as well as antagonists for the androgen receptor. Compounds 1, 2, 3, 4 and 5 showed the following inhibitory activity for the 5alpha-reductase enzyme with IC(50) values of: 1 (1.65 microM), 2 (10 microM), 3 (19 nM), 4 (100 nM) and 5 (100 nM). The results of this study also showed the effect of increasing concentrations of the novel steroids upon [(3)H]dihydrotestosterone binding to androgen receptors from male hamster prostate. The K(i) values for compounds 1, 2, 3, 4, 5 and dihydrotestosterone showed the following order of affinity for the androgen receptor: 4>5>dihydrotestosterone>2>3>1. The overall data indicated that all synthesized compounds 1, 2, 3, 4 and 5 are inhibitors of the 5alpha-reductase enzyme present in the hamster prostate. In addition compounds 1, 2, 3, 4 and 5 also presented an affinity for the androgen receptor.     

Rhodium(I) and rhodium(III) arene complexes with N-carbazolyltriphenylphosphinegold(I) and other polycyclic arene ligands

The new heteronuclear arene complexes [(COD)Rh(μ-cbz)AuPPh₃]ClO₄, [{(COD)Rh}₂(μ-cbz)AuPPh₃](ClO₄)₂, [(C₅Me₅)Rh(μ-cbz)AuPPh₃](ClO₄)₂ and [{C₅Me₅) Rh}₂(μ-cbz)AuPPh₃](ClO₄)₄ (COD = 1,5-cyclooctadiene, cbz = carbazolyl), and the mononuclear arene complexes [(COD)Rh(arene)]ClO₄ (arene = tetralin, biphenyl, fluorene, indene, 9,10-dihydroanthracene or carbazole) have been prepared by reaction of the acetone solvated complexes [(COD)Rh(Me₂CO)_x]ClO₄ or [(C₅Me₅)Rh(Me₂CO)₃](ClO₄)₂ with (cbz)AuPPh₃ or the appropriate polycyclic arene ligand.